The Omicron variant of the coronavirus does not have a negative effect on cardiovascular health in young adults who have been vaccinated, a small study suggests. Additionally, women should not delay routine mammograms after receiving a COVID-19 mRNA vaccine, experts now say.
Inovio Pharmaceuticals announced a leadership change at the helm and the discontinuation of a Phase III COVID-19 vaccine study.
Novavax shared positive initial results from the Phase I/II clinical study of the company’s proposed combination vaccine for COVID-19.
Unvaccinated people infected with the Omicron variant are unlikely to develop immune responses that will protect them against other variants of the coronavirus, a new study suggests. Additionally, the average number of global deaths from COVID-19 were 6 percent higher on weekends compared to weekdays throughout the pandemic, according to statistics reported to the World Health Organization between March 2020 and March 2022.
Silverback Therapeutics is halting the company’s clinical oncology programs and letting go of about 27% of its workforce as part of a restructuring initiative that would leave Silverback with more cash reserves.
The Omicron variant of the coronavirus is causing a dramatic rise in cases of croup, a dangerous respiratory condition usually seen in babies and toddlers, new data suggest. Additionally, new research sheds light on how a tuberculosis vaccine might help protect against COVID-19.
Medicago’s vaccine on February 24 became the world’s first plant-based shot approved against COVID-19 after Health Canada cleared Covifenz for use in adults.
The immune response to COVID-19 helps protect against reinfection, but that protection is weaker against Omicron than it was against earlier variants of the coronavirus, according to new data. In other news, protection provided by booster shots of the mRNA vaccines from Moderna Inc. or Pfizer Inc. and partner BioNTech SE starts waning quickly, according to data published in Feb. 11th’s Morbidity and Mortality Weekly Report from the U.S. Centers for Disease Control and Prevention (CDC).
Novavax Inc.’s Covid-19 vaccine is effective in generating an immune response against the Omicron variant, according to early data published on December 22, suggesting that the U.S. drugmaker’s existing Covid-19 vaccine can help combat the new Omicron variant.
A major British study into mixing Covid-19 vaccines found that people had a better immune response when they received a first dose of AstraZeneca or Pfizer-BioNTech shots followed by Moderna nine weeks later, according to the results on December 6.